video

Source: Taiwan English News

An explosion at a pharmaceutical factory in Taoyuan City left two injured and caused a fire early this afternoon, December 20.

People as far as Tamsui District in New Taipei City reported hearing the massive blast shortly after noon. Immediately after the blast, thick black smoke could be seen pouring out of the SCI Pharmtech factory.

Firefighters responding to the fire found two people injured. A 30-year-old foreign migrant worker suffered third-degree burns to 80%-90% of his body, and is described as being in a critical condition.

A 40-year-old man suffered a burn to one hand. Both men were sent to Chang Gung Memorial Hospital for treatment.

While the factory is located close to Taipei Taoyuan International Airport, operations at the airport were not affected, according to reports in United Daily News and ET Today.

The Taoyuan City Fire Department dispatched 76 personnel, 28 fire appliances and 2 ambulances to the scene of the fire.

The cause of the explosion is currently under investigation.

Liberty Times reported that the factory produces hydroxychloroquine APIs, and is the world’s second largest HCQ raw material supplier.











Related:
Inhalable liposomal hydroxychloroquine (TLC19) may provide clinical benefit and serve as a potential treatment for COVID-19: Taiwan & California

A massive hydroxychloroquine meta-analysis (156 studies) has just been updated (version 28!).It says that HCQ works beyond all statistical doubt.

Hydroxychloroquine: Taiwan builds up stocks

‘Only a one in 17 billion chance hydroxychloroquine doesn’t work’: medical professor

How hydroxychloroquine works at the cellular level

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »